Sartorius Stedim Biotech SA (DIM) - Total Liabilities
Based on the latest financial reports, Sartorius Stedim Biotech SA (DIM) has total liabilities worth €3.67 Billion EUR (≈ $4.29 Billion USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore investment intensity of Sartorius Stedim Biotech SA to see how much of total assets are deployed in long-term investments.
Sartorius Stedim Biotech SA - Total Liabilities Trend (2005–2025)
This chart illustrates how Sartorius Stedim Biotech SA's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of Sartorius Stedim Biotech SA.
Sartorius Stedim Biotech SA Competitors by Total Liabilities
The table below lists competitors of Sartorius Stedim Biotech SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CELLN.TELEC.UNSP.ADR/1/2
F:4720
|
Germany | €28.80 Billion |
|
Alliant Energy Corp
NASDAQ:LNT
|
USA | $17.39 Billion |
|
KUBOTA CORP. ADR/20
F:KUOA
|
Germany | €3.33 Trillion |
|
CNH Industrial N.V.
NYSE:CNH
|
USA | $34.32 Billion |
|
IHH Healthcare Bhd
KLSE:5225
|
Malaysia | RM23.52 Billion |
|
Banco Santander Chile
SN:BSANTANDER
|
Chile | CL$65.00 Trillion |
|
Lundin Gold Inc
TO:LUG
|
Canada | CA$316.25 Million |
|
Toast Inc
NYSE:TOST
|
USA | $1.14 Billion |
Liability Composition Analysis (2005–2025)
This chart breaks down Sartorius Stedim Biotech SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Sartorius Stedim Biotech SA (DIM) balance sheet quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.87 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sartorius Stedim Biotech SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sartorius Stedim Biotech SA (2005–2025)
The table below shows the annual total liabilities of Sartorius Stedim Biotech SA from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €3.89 Billion ≈ $4.55 Billion |
-8.06% |
| 2024-12-31 | €4.23 Billion ≈ $4.95 Billion |
-16.46% |
| 2023-12-31 | €5.07 Billion ≈ $5.92 Billion |
+98.60% |
| 2022-12-31 | €2.55 Billion ≈ $2.98 Billion |
+15.03% |
| 2021-12-31 | €2.22 Billion ≈ $2.59 Billion |
+39.80% |
| 2020-12-31 | €1.59 Billion ≈ $1.85 Billion |
+146.80% |
| 2019-12-31 | €642.79 Million ≈ $751.49 Million |
+22.07% |
| 2018-12-31 | €526.59 Million ≈ $615.64 Million |
+0.41% |
| 2017-12-31 | €524.45 Million ≈ $613.14 Million |
+21.32% |
| 2016-12-31 | €432.29 Million ≈ $505.40 Million |
+3.19% |
| 2015-12-31 | €418.92 Million ≈ $489.76 Million |
+13.76% |
| 2014-12-31 | €368.25 Million ≈ $430.52 Million |
-5.43% |
| 2013-12-31 | €389.39 Million ≈ $455.24 Million |
+8.42% |
| 2012-12-31 | €359.14 Million ≈ $419.88 Million |
+10.49% |
| 2011-12-31 | €325.04 Million ≈ $380.00 Million |
+11.59% |
| 2010-12-31 | €291.27 Million ≈ $340.52 Million |
+6.05% |
| 2009-12-31 | €274.66 Million ≈ $321.10 Million |
-2.15% |
| 2008-12-31 | €280.70 Million ≈ $328.16 Million |
+0.98% |
| 2007-12-31 | €277.96 Million ≈ $324.97 Million |
+33.37% |
| 2006-12-31 | €208.41 Million ≈ $243.65 Million |
-2.69% |
| 2005-12-31 | €214.18 Million ≈ $250.39 Million |
-- |
About Sartorius Stedim Biotech SA
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transp… Read more